Ocean Biomedical’s cancer-targeting antibody candidate shows effective tumor reduction against a subset of NSCLC with EGFR mutations
Ocean Biomedical, Inc. (NASDAQ: OCEA), a biotechnology company that operates by partnering with leading researchers to accelerate new discoveries in ...